Compare SMX Security Matters plc (SMX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs Travere Therapeutics Inc. Common Stock — how do they compare? SMX Security Matters plc trades at $3.7 (market cap $4.09M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 1193.2× SMX Security Matters plc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SMX Security Matters plc for 22 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SMX | TVTX | |
|---|---|---|
Market Cap | $4.09M | $4.88B |
Volume | 108,612 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $74.08K | $67.52 |
52-Week Low | $3.56 | $26.79 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | -$27.23M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX stock trades at $3.79, up 4.7% today, but faces severe fundamental challenges with no revenue reported for 2025 and a net loss of $169.18 million. The technical outlook is bearish based on moving averages, though oversold oscillators suggest potential for a near-term bounce. The company is actively promoting its Digital Material Passport technology for recycling and material verification, generating significant media coverage in outlets like Forbes and TIME as of late September 2026.
The investment case is highly speculative. While the company's technology narrative is gaining media traction, the absence of revenue and deeply negative profitability metrics present substantial risk. Investor optimism appears driven by the long-term potential of its circular economy platform rather than current financial performance, making the stock suitable only for risk-tolerant investors betting on a successful business turnaround.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
